Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.70 |
| ▸ | MGLL | Q99685 | 1/20 | 0.70 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.64 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.64 |
| ▸ | CASP3 | P42574 | 5/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24836231 | 0.92 | FAAH (0.81) | FAAHMGLLKAT2AKAT2BCASP3 | |
| SCHEMBL24836228 | 0.90 | FAAH (0.84) | FAAHMGLLKAT2AKAT2BCASP3 | |
| SCHEMBL8070856 | 0.88 | CASP3 (0.66) | FAAHMGLLKAT2AKAT2BCASP3 | |
| SCHEMBL24836229 | 0.88 | FAAH (0.76) | FAAHMGLLKAT2AKAT2BCASP3 | |
| SCHEMBL11278746 | 0.84 | CASP3 (0.74) | FAAHMGLLKAT2AKAT2BCASP3 | |
| SCHEMBL3147758 | 0.84 | FAAH (0.97) | FAAHMGLLKAT2AKAT2BCASP3 | |
| SCHEMBL17372961 | 0.84 | FAAH (0.70) | FAAHMGLLKAT2AKAT2BCASP3 | |
| SCHEMBL9594067 | 0.84 | FAAH (0.70) | FAAHMGLLKAT2AKAT2BCASP3 | |
| SCHEMBL24327898 | 0.83 | FAAH (1.00) | FAAHMGLLKAT2AKAT2BCASP3 | |
| SCHEMBL8621525 | 0.83 | FAAH (1.00) | FAAHMGLLKAT2AKAT2BCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6133275-A | ALPHA 1 ADRENORECEPTOR ANTAGONISTS; TREATING BENIGN PROSTATIC HYPERPLASIA AND OTHER UROLOGICAL DISEASES E.G., BLADDER OUTLET OBSTRUCTION), NEUROGENIC BLADDER AND GYNECOLOGICAL SYNDROMES, E.G., DYSMENORRHEA; UTERINE MUSCLE RELAXANTS | ABBOTT LABORATORIES (US) | 2000-10-17 | — | — | US | disclosed |
| US-5510374-A | USEFUL IN TREATMENT OF DISORDERS OF THE SEROTINERGIC SYSTEM | ADIR ET COMPAGNIE (FR) | 1996-04-23 | — | — | US | disclosed |
| US-5346916-A | FOR TREATING ANIMALS SUFFERING FROM DISORDERS OF THE SEROTONINERGIC SYSTEM | ADIR ET COMPAGNIE (FR) | 1994-09-13 | — | — | US | disclosed |
| US-5314907-A | 3-aminochroan compounds | ADIR ET COMPAGNIE (FR) | 1994-05-24 | — | — | US | disclosed |
| US-5273994-A | Also hydroxy- or alkyl ether-substituted | ADIR ET COMPAGNIE (FR) | 1993-12-28 | — | — | US | disclosed |
| US-5252578-A | Treatment of disorders of teh serotoninergic system | ADIR ET COMPAGNIE (FR) | 1993-10-12 | — | — | US | disclosed |
| EP-0452204-A1 | 3-Aminochromane derivatives, procedure for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1991-10-16 | — | — | EP | disclosed |